• Explore /
  • Poster
  • / TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase 3 RECOURSE trial.

TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase 3 RECOURSE trial.

Abstract Poster

Authors

Robert Mayer

Robert J. Mayer

Dana-Farber Cancer Institute, Boston, MA

Robert J. Mayer , Atsushi Ohtsu , Takayuki Yoshino , Alfredo Falcone , Rocio Garcia-Carbonero , Josep Tabernero , Alberto F. Sobrero , Marc Peeters , Fabio Benedetti , Lukas Makris , Hiroshi Ambe , Alberto Zaniboni , Yasuhiro Shimada , Kentaro Yamazaki , Yoshito Komatsu , Howard S. Hochster , Heinz-Josef Lenz , Ben Tran , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01607957

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 634)

DOI

10.1200/jco.2016.34.4_suppl.634

Abstract #

634

Poster Bd #

G17

Abstract Disclosures

Similar Posters

First Author: Atsushi Ohtsu

First Author: David H. Ilson

First Author: Atsushi Ohtsu

First Author: Atsushi Ohtsu